|
|
Article: X-CELL MEDICAL COMPLETES ENROLLMENT FOR ETHOS I TRIAL.
- Article from:
- Biotech Equipment Update
- Article date:
- January 1, 2006
CopyrightCOPYRIGHT 2006 Worldwide Videotex. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
X-Cell Medical, Inc., Princeton, N.J., has completed enrollment in its multinational clinical trial to study the safety and effectiveness of the ETHOS I Coronary Stent System.
ETHOS I stents are coated with slow-release and moderate- release formulations of 17 beta-estradiol, an approved and safe drug used in hormone replacement therapy and other indications. An overview of the potential cardioprotective and safety benefits of using estradiol to reduce restenosis in human coronary arteries and the ETHOS I study design was presented at the 2005 Transcatheter Cardiovascular Therapeutic symposium (TCT) by Alexandre Abizaid, MD, PhD of the Cardiovascular Research ...